Gilead Sciences Inc (GILD)
Gilead - U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Gilead - U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
WD-40 Company Declares Regular Quarterly Dividend and Schedules Third Quarter 2026 Earnings Conference Call
Forum Energy Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference
HII Leads Successful DefenseTech LIVE Event, Advancing Speed, Integration, and Mission Driven Innovation
Park Ha Biological Technology Co., Ltd. Announces Closing of $2.0 Million Registered Direct Offering
PN Smart Energy Limited Announces Official Name Change to Reaffirm Its IPP Strategy
Monika Saxena Named Brand President of BJ’s Restaurants, Inc.
Apollo Commercial Real Estate Finance, Inc. Declares Quarterly Common Stock Dividend and Provides Update on Review of Strategic Alternatives
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update